Hyaluronidase & Filler Dissolving: A UK Practitioner Guide

Evidence reviewed: September 2026. Hyaluronidase is often described as a “filler dissolver”, but that shorthand can obscure the most important clinical point: elective correction of unwanted hyaluronic acid (HA) filler and emergency treatment of suspected HA filler-induced vascular occlusion are different clinical scenarios. The indication should be established before concentration, timing, reassessment and escalation are considered.

Quick answer: Hyaluronidase can degrade HA dermal filler. It does not dissolve every filler type. In the UK, Hyalase 1500 I.U. is a prescription-only medicine and cosmetic HA-filler reversal is an off-label use because it is not an indication listed in the current UK SmPC.

Hyaluronidase dosing at a glance

What is hyaluronidase?

Hyaluronidase is an enzyme with a temporary, reversible depolymerising effect on hyaluronic acid in connective tissue. In aesthetic medicine it is used off-label to degrade HA dermal filler. The UK Hyalase SmPC states that each ampoule contains 1,500 international units.

The SmPC's licensed indications concern enhancing permeation of certain injections/infusions and promoting resorption of excess fluids and blood in tissues. Cosmetic dermal-filler reversal is not listed. Practitioners should therefore distinguish the medicine's licensed product information from professional guidance governing its off-label aesthetic use.

Can all dermal fillers be dissolved?

No. Hyaluronidase acts on hyaluronic acid. It is not a universal antidote for all injectable implants. PLLA, calcium hydroxylapatite and other non-HA materials should not be described as “dissolvable” with hyaluronidase.

Where the original filler is uncertain, product history matters. Treatment records, patient-held information, clinic records and—where clinically appropriate and available—imaging may help clarify what is present. A poor aesthetic outcome should not automatically be labelled “migration”.

Elective filler dissolving versus vascular occlusion

Elective correction may be considered for problems such as unwanted HA volume, asymmetry, inappropriate placement or clinically assessed migration. Suspected vascular occlusion is different: it is a potentially tissue-threatening complication requiring immediate recognition and management.

Longeva's separate vascular occlusion guide covers the broader CMAC management framework. Practitioners should also be familiar with the differential diagnosis of inflammatory and infectious complications; see our guide to delayed-onset nodules after aesthetic injectables.

What dose of hyaluronidase is used for elective filler dissolving?

There is no single evidence-based dose that applies to every elective HA-filler correction. Published literature contains varied dosing approaches. CMAC therefore recommends treating to effect rather than relying on a fixed dose and advises against concentrations below 1,500 IU in 5 mL.

This distinction matters. “1,500 IU in 5 mL” describes the minimum concentration recommended by that guidance; it does not mean every patient requires the whole 1,500 IU or that every area should receive the same volume.

HA filler behaviour varies with product characteristics including cross-linking and gel properties, as well as the volume present, anatomical site, tissue integration and time since implantation. A universal rule such as “X units per 0.1 mL filler” can therefore create false precision.

When should elective dissolution be reassessed?

CMAC states that an elective patient can be assessed after 48 hours and treatment repeated if necessary. Post-procedural swelling can persist beyond this point, so visible appearance alone must be interpreted carefully.

The same guidance recommends waiting a minimum of two weeks before re-treating with cross-linked HA filler, and longer where significant swelling persists, to allow a more predictable aesthetic assessment.

What dose is used for suspected vascular occlusion?

For established HA filler-induced vascular occlusion, CMAC recommends reconstituting 1,500 IU hyaluronidase with 1 mL bacteriostatic 0.9% sodium chloride or 1–2% lidocaine (or a suitable alternative). Its published protocol then calls for infiltration of 1,500 IU across the course of the affected artery and the wider area of ischaemia.

CMAC specifically notes that more than one vial may be required where a significant area is affected and advises focusing on complete coverage rather than an arbitrary total number of units. Perfusion is reassessed and management continues according to the current complication protocol and clinical response.

Suspected visual compromise is an ophthalmic emergency. It should not be treated as routine filler dissolution and requires immediate emergency escalation according to current local and professional pathways.

Why does filler type affect dissolution?

HA fillers are not interchangeable gels. Differences in cross-linking, HA concentration, rheology and tissue integration can alter susceptibility to enzymatic degradation. A filler that responds quickly in one clinical setting does not establish a universal dose for another product or anatomical site.

This is also why knowing whether the implant is HA or non-HA is fundamental. Our HA versus non-HA dermal filler guide explains the broader material differences, while our Juvederm vs Restylane comparison looks at two major HA filler families.

Does lip filler migration always need dissolving?

No. “Migration” is frequently used online as a catch-all description. A lip irregularity may instead represent oedema, asymmetry, product placement, overcorrection, palpable filler, an inflammatory nodule or another complication. Diagnosis comes before treatment.

Elective dissolution also does not have to mean an indiscriminate “full dissolve”. Targeted correction may be clinically appropriate, but diffusion and variable filler susceptibility mean the result cannot be assumed to remain perfectly confined to an intended millimetre-scale area. That uncertainty belongs in consent.

How quickly does hyaluronidase dissolve filler?

Enzymatic activity begins rapidly, but the patient's visible aesthetic endpoint is not necessarily immediate. Injection-related swelling, the original tissue response and the amount and type of filler can obscure the result. This is one reason CMAC's elective guidance supports reassessment rather than reflexive repeated dosing on the same aesthetic appearance.

Does hyaluronidase remove the body's natural HA?

Hyaluronidase is not selective only for manufactured dermal filler; endogenous HA is also a substrate. CMAC notes the rapid turnover of native HA and cites restoration within approximately 15–20 hours. That does not justify unnecessary treatment, but it helps explain why concern about native HA should not lead to undertreatment of a genuine clinical indication—particularly an emergency.

Hyalase safety and contraindications

The current UK SmPC contraindicates Hyalase in patients with hypersensitivity to hyaluronidase. It also states that it should not be administered intravenously, used to reduce swelling from bites or stings, or used at sites of infection or malignancy. Severe allergic reactions including anaphylaxis have been reported rarely.

The SmPC states that prepared solution should be used immediately and unused contents discarded. It also reports physical incompatibility with heparin and adrenaline and identifies furosemide, benzodiazepines and phenytoin as incompatible. Practitioners should consult the current SmPC rather than relying on a remembered preparation recipe.

Should you skin test before using hyaluronidase?

The answer depends on context and current guidance. A suspected vascular occlusion is time-critical. CMAC's vascular-occlusion guidance does not support delaying urgent treatment for routine skin testing. Elective practice allows a different risk-benefit assessment and should follow current professional guidance, local medicines policy, prescriber judgement and the individual patient's history.

What should be documented for elective filler dissolution?

Documentation should be proportionate to the use of a prescription medicine and the clinical problem being treated. Relevant records can include the assessment and differential diagnosis, original filler where known, anatomical findings, indication for reversal, off-label discussion, allergy history, consent, medicine and batch details, preparation used, treatment area, clinical endpoint, photographs where appropriate, adverse events, aftercare and planned review.

What should a clinic have in place before offering filler dissolution?

Hyaluronidase should sit within a wider complication-management system rather than existing as a vial in a cupboard. Clinics need appropriate prescribing and medicines governance, storage and stock controls, emergency equipment, anaphylaxis preparedness, escalation pathways, practitioner competence and clear documentation processes. See Longeva's aesthetic emergency kit guide and POM ordering and practitioner verification guide.

Seven common hyaluronidase mistakes

1. Calling every poor filler result “migration”.
2. Assuming all fillers can be dissolved. Hyaluronidase is relevant to HA, not every implant material.
3. Using a universal units-per-filler formula. Product and clinical variables matter.
4. Confusing elective and emergency concentrations. The clinical objectives are fundamentally different.
5. Treating the SmPC's licensed posology as an aesthetic protocol. Cosmetic HA reversal is off-label.
6. Judging the final aesthetic result too early. Swelling can obscure the endpoint.
7. Having the medicine without the governance. Prescribing, consent, documentation, emergency readiness and escalation are part of safe practice.

Frequently asked questions

Does Hyalase dissolve dermal filler?

Hyalase contains hyaluronidase and can degrade hyaluronic-acid filler. It is not a universal dissolver for non-HA products.

Is Hyalase licensed for cosmetic filler dissolving in the UK?

No. Hyalase is a prescription-only medicine, but cosmetic HA-filler reversal is not an indication listed in the current UK SmPC. Its use for this purpose is off-label.

Is 1,500 IU always the correct dose?

No. Hyalase contains 1,500 IU per ampoule, but ampoule strength is not synonymous with a universal patient dose. Elective reversal and vascular-occlusion management use different strategies.

What does 1,500 IU in 5 mL mean?

In CMAC's elective guidance it is a concentration recommendation: CMAC advises against concentrations lower than 1,500 IU in 5 mL and recommends treating to effect. It is not an instruction that all 5 mL must be injected into every patient.

How soon can filler be replaced after dissolving?

CMAC recommends waiting at least two weeks before re-treatment with cross-linked HA filler, and longer if significant swelling remains, to improve predictability of the aesthetic assessment.

Can you partially dissolve lip filler?

Targeted elective correction may be possible, but the enzymatic effect cannot be assumed to remain perfectly confined. The likely benefits, uncertainty and possibility of further correction should form part of consent.

Does hyaluronidase dissolve Sculptra or Radiesse?

No. Sculptra is PLLA-based and Radiesse is calcium-hydroxylapatite-based; hyaluronidase should not be represented as a dissolving agent for these non-HA materials.

Practitioner takeaway

Hyaluronidase is best understood as a prescription medicine used against a defined clinical indication—not simply as a generic “filler dissolver”. For elective HA correction, current CMAC guidance favours treatment to effect and reassessment rather than a universal filler-to-enzyme conversion. For suspected HA filler-induced vascular occlusion, the concentration, urgency and treatment objective are different and current emergency guidance should be followed.

For UK practitioners, the safest hierarchy is: identify the clinical problem → establish the likely filler material → distinguish elective correction from emergency vascular compromise → use current SmPC and professional guidance → document, reassess and escalate appropriately.

References and further reading

• Wockhardt UK Ltd. Hyalase 1500 I.U. — Summary of Product Characteristics (eMC).
• King M, Convery C, Davies E. Guideline for the Safe Use of Hyaluronidase in Aesthetic Medicine, Including Modified High-dose Protocol.
• Murray G, Convery C, Walker L, Davies E. Guideline for the Management of Hyaluronic Acid Filler-induced Vascular Occlusion.

Professional information only. This article is intended for appropriately qualified UK healthcare and aesthetic professionals. It does not replace the current SmPC, patient-specific prescribing judgement, local medicines governance, emergency pathways or practical complication-management training. Guidance can change; practitioners should check current primary sources at the point of care.